Brief: Rubius Therapeutics To Present Trials In Progress Poster For The Phase 1/2 Clinical Trial Of Rtx-224 In Select Advanced Solid Tumors At The 2022 American Society Of Clinical Oncology Annual Meeting
27/05/2022 24:43
May 26 (Reuters) - Rubius Therapeutics Inc RUBY.O :
* RUBIUS THERAPEUTICS TO PRESENT TRIALS IN PROGRESS POSTER
FOR THE
PHASE 1/2 CLINICAL TRIAL OF RTX-224 IN SELECT ADVANCED SOLID
TUMORS AT THE 2022 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL
MEETING
Source text for Eikon: ID:nGNX5LwwGp
Further company coverage: RUBY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rubius Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Apple, TCR2 Therapeutics, Silvergate Capital
Brief: Rubius Therapeutics Inc - Nasdaq Notified Co That Trading In Co's Stock Will Be Suspended Upon Opening Of Business On March 7, 2023
Brief: Rubius Therapeutics Board Of Directors Approved Plan Of Liquidation And Dissolution Of Company
Rubius Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Baidu, Boeing, Microsoft